Genetic Technologies unveils comprehensive genetic risk assessment test
Genetic Technologies Limited (GTG), a global leader in guideline-driven genomics-based testing for health, wellness, and serious diseases, has unveiled its most advanced risk assessment test to date. This innovation builds upon the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test, introducing a pioneering approach to identifying disease risk across a broader spectrum. The new test, set to be a world first, incorporates over 200 high-penetrant genes, offering an unprecedented level of insight into hereditary risks associated with the most common cancers, cardiovascular disease, and type 2 diabetes.
GTG’s latest innovation represents a significant milestone in the field of personalized healthcare. For the first time, doctors can identify nearly 100% of individuals at risk of serious diseases, going beyond the limitations of family history, which accounts for only 5-15% of disease risk. Importantly, this comprehensive test also covers sporadic non-hereditary diseases, addressing the risk factors for the remaining 85% of the population.
This population-wide test is poised to make a profound impact, with the potential to identify individuals at risk of conditions contributing to nearly 70% of annual mortalities and morbidities. Its non-invasive saliva-based methodology underscores GTG’s commitment to accessible, patient-friendly testing options without compromising on accuracy or reliability.
Key Features of GeneType’s Risk Assessment Test
Extensive Genetic Panel: Incorporating more than 200 high-penetrant genes, GeneType’s test goes beyond traditional assessments by ensuring a comprehensive evaluation of an individual’s genetic predisposition to serious diseases, irrespective of family history.
Innovative Saliva Test: Staying true to GeneType’s patient-centric approach, the test leverages a patented non-invasive saliva sample, making it an accessible option for widespread use.
Diverse Disease Coverage: The test’s extensive coverage includes not only oncological conditions but also cardiovascular and metabolic diseases, offering a holistic view of an individual’s health risks.
The United States healthcare market presents a significant opportunity for the widespread adoption of GeneType’s innovative test. With personalized medicine and preventative healthcare gaining traction, the demand for comprehensive genetic risk assessments is expected to surge. The genetic testing market in the United States, valued at over $7.4 billion in 2022, highlights the growing awareness and preference for genetic testing as a tool for disease prevention and early intervention.
GTG’s CEO, Simon Morriss, expressed enthusiasm about the launch of the GeneType Comprehensive Risk Assessment Test, stating, “As pioneers in risk assessment testing, we are thrilled to introduce our latest innovation. This test empowers individuals to take control of their health and enables healthcare professionals to deliver truly personalized care, resulting in a significant improvement in patient outcomes.”
GeneType’s test is poised to redefine the landscape of personalized preventative healthcare, offering a transformative tool for healthcare providers and patients alike. As the company advances its commitment to genetically informed diagnostics, the Comprehensive Risk Assessment Test stands as a testament to the potential of genomics in shaping the future of healthcare, tailored to every individual’s unique genetic makeup.